Needham & Company LLC Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock

Praxis Precision Medicines (NASDAQ:PRAX) had its price target lifted by stock analysts at Needham & Company LLC from $575.00 to $582.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 61.33% from the company’s previous close.

Several other equities analysts have also weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Praxis Precision Medicines in a report on Wednesday, May 27th. Piper Sandler reiterated an “overweight” rating on shares of Praxis Precision Medicines in a research report on Monday, July 13th. The Goldman Sachs Group started coverage on Praxis Precision Medicines in a research note on Monday, July 13th. They issued a “buy” rating and a $447.00 price target on the stock. Jefferies Financial Group restated a “buy” rating on shares of Praxis Precision Medicines in a research report on Thursday, May 7th. Finally, Truist Financial set a $616.00 price objective on Praxis Precision Medicines and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Four analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $573.05.

Praxis Precision Medicines Trading Down 2.5%

Shares of NASDAQ:PRAX opened at $360.76 on Thursday. Praxis Precision Medicines has a 1-year low of $37.19 and a 1-year high of $382.54. The stock has a market capitalization of $10.06 billion, a P/E ratio of -27.90 and a beta of 2.78. The business has a 50-day moving average price of $303.99 and a two-hundred day moving average price of $315.79.

Praxis Precision Medicines (NASDAQ:PRAX) last issued its earnings results on Thursday, August 6th. The company reported ($2.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.67) by $0.80. As a group, equities analysts predict that Praxis Precision Medicines will post -14.82 EPS for the current year.

Insiders Place Their Bets

In other Praxis Precision Medicines news, Director Jill Desimone sold 11,600 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $311.32, for a total value of $3,611,312.00. Following the sale, the director directly owned 2,337 shares in the company, valued at approximately $727,554.84. This trade represents a 83.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.00% of the company’s stock.

Institutional Trading of Praxis Precision Medicines

Several hedge funds have recently added to or reduced their stakes in PRAX. Bank of New York Mellon Corp bought a new position in Praxis Precision Medicines during the second quarter worth about $28,583,000. Handelsbanken Fonder AB acquired a new stake in shares of Praxis Precision Medicines during the second quarter worth about $3,294,000. GAMMA Investing LLC raised its position in shares of Praxis Precision Medicines by 10.3% during the second quarter. GAMMA Investing LLC now owns 332 shares of the company’s stock worth $111,000 after purchasing an additional 31 shares during the period. Parallel Advisors LLC lifted its holdings in shares of Praxis Precision Medicines by 3,000.0% during the 1st quarter. Parallel Advisors LLC now owns 124 shares of the company’s stock valued at $40,000 after purchasing an additional 120 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its holdings in shares of Praxis Precision Medicines by 2.0% during the 1st quarter. Perceptive Advisors LLC now owns 2,035,986 shares of the company’s stock valued at $655,974,000 after purchasing an additional 40,000 shares in the last quarter. Institutional investors and hedge funds own 67.84% of the company’s stock.

Key Praxis Precision Medicines News

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: Praxis said it expects two FDA decisions within roughly six months and is targeting approximately $10 billion in peak sales for ulixacaltamide. The company is also preparing a commercial organization of about 300 field employees, signaling confidence in the drug’s market potential. Praxis signals two FDA decisions and targets $10 billion in peak sales
• Positive Sentiment: Management’s planned commercial launch could exceed expectations if regulatory approvals are secured and adoption develops as projected, strengthening the long-term growth narrative for PRAX. Praxis commercial launch could smash expectations
• Positive Sentiment: Praxis reported a second-quarter loss of $2.87 per share, narrower than the $3.67 analyst consensus, providing a better-than-expected earnings result. Needham & Company also raised its price target from $575 to $582 and maintained a Buy rating. Needham raises Praxis price target Praxis corporate update and second-quarter results
• Neutral Sentiment: The company remains unprofitable and expects a full-year loss, while building a sizeable commercial infrastructure ahead of potential approvals. Those investments could increase expenses before product revenue begins.
• Negative Sentiment: With PRAX near its 52-week high, a market capitalization above $10 billion, and a high beta, the stock is vulnerable to valuation-driven profit-taking. Investors may also be locking in gains while awaiting the FDA decisions and clearer evidence of launch execution.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.